EPH receptors and ephrins

Modern Concepts in Angiogenesis

Volumn , Issue , 2007, Pages 27-66

  Pasquale, Elena B ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77649101529     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949456_0002     Document Type: Chapter

References (98)

1. Pasquale EB (2005). Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6: 462-475.
2. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F (1987). A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238: 1717-1720.
3. Eph-Nomenclature-Committee (1997). Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 90: 403-404.
4. Bartley TD, Hunt RW, Welcher AA, et al. (1994). B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 368: 558-560.
5. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM (1995). Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268: 567-569.
6. Holmberg J, Clarke DL, Frisen J (2000). Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408: 203-206.
7. Palmer A, Zimmer M, Erdmann KS, et al. (2002). EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol Cell 9: 725-737.
8. Song J (2003). Tyrosine phosphorylation of the well packed ephrinB cytoplasmic beta-hairpin for reverse signaling. Structural consequences and binding properties. J Biol Chem 278: 24714-24720.
9. Cowan CA, Henkemeyer M (2001). The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 413: 174-179.
10. Pasquale EB (2004). Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 7: 417-418.
11. Miao H, Burnett E, Kinch M, Simon E, Wang B (2000). Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2: 62-69.
12. Dohn M, Jiang JY, Chen XB (2001). Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20: 6503-6515.
13. Stein E, Lane AA, CerrettiDP, et al. (1998). Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, assembly responses. Genes Dev 12: 667-678.
14. Brantley DM, Cheng N, Thompson EJ, et al. (2002). Soluble Eph A, receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026.
15. Dobrzanski P, Hunter K, Jones-Bolin S, et al. (2004). Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910-919.
16. Sarma V, Wolf FW, Marks RM, Shows TB, Dixit VM (1992). Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro. J Immunol 148: 3302-3312.
17. Daniel TO, Stein E, Cerretti DP, et al. (1996). ELK and LERK-2 in developing kidney and microvascular endothelial assembly. Kidney Int - Suppl 57: S73-81.
18. Myers C, Charboneau A, Boudreau N (2000). Homeobox B3 promotes capillary morphogenesis and angiogenesis. J Cell Biol 148: 343-351.
19. Cheng N, Brantley DM, Liu H, et al. (2002). Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 2-11.
20. Brantley-Sieders DM, Caughron J, HicksD, et al. (2004). EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 117: 2037- 2049.
21. Ogawa K, Pasqualini R, Lindberg RA, et al. (2000). The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052.
22. Pandey A, Lazar DF, Saltiel AR, DixitVM (1994). Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J Biol Chem 269: 30154-30157.
23. Ogita H, Kunimoto S, Kamioka Y, et al. (2003). EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in vascular smooth muscle cells. Circ Res 93: 23-31.
24. Deroanne C, Vouret-Craviari V, Wang B, Pouyssegur J (2003). EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J Cell Science 116: 1367-1376.
25. Adams RH, Wilkinson GA, Weiss C, et al. (1999). Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, sprouting angiogenesis. Genes Dev 13: 295-306.
26. Kim I, Ryu YS, Kwak HJ, et al. (2002). EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J 16: 1126-1128.
27. SawaiY, Tamura S, Fukui K, et al. (2003). Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. J Hepatol 39: 991-996.
28. Steinle JJ, Meininger CJ, Forough R, et al. (2002). Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 277: 43830-43835.
29. Huynh-Do U, Stein E, Lane AA, et al. (1999). Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J 18: 2165-2173.
30. Hayashi S, Asahara T, Masuda H, Isner JM, Losordo DW (2005). Functional ephrin-B2 expression for promotive interaction between arterial and venous vessels in postnatal neovascularization. Circulation 111: 2210-2218.
31. Becker E, Huynh-Do U, Holland S, et al. (2000). Nck-interacting Ste20 kinase couples Eph receptors to c-Jun N-terminal kinase and integrin activation. Mol Cell Biol 20: 1537-1545.
32. Vindis C, Teli T, Cerretti DP, Turner CE, Huynh-Do U (2004). EphB1-mediated cell migration requires the phosphorylation of paxillin at Tyr-31/Tyr-118. J Biol Chem 279: 27965-27970.
33. Vindis C, Cerretti DP, Daniel TO, Huynh-Do U (2003). EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis. J Cell Biol 162: 661-671.
34. Nagashima K, Endo A, Ogita H, et al. (2002). Adaptor protein crk is required for Ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. Mol Biol Cell 13: 4231-4242.
35. Maekawa H, Oike Y, Kanda S, et al. (2003). Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature. Arterioscler Thromb Vasc Biol 23: 2008-2014.
36. Hamada K, Oike Y, Ito Y, et al. (2003). Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol 23: 190-197.
37. Fuller T, Korff T, Kilian A, Dandekar G, Augustin HG (2003). Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 116: 2461-2470.
38. NorenNK,LuM,Freeman AL,KoolpeM,PasqualeEB (2004). Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 101: 5583-5588.
39. Adams RH, Diella F, Hennig S, et al. (2001). The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 104: 57-69.
40. Huynh-Do U, Vindis C, Liu H, et al. (2002). Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J Cell Sci 115: 3073-3081.
41. Bruhl T, Urbich C, Aicher D, et al. (2004). Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res 94: 743-751.
42. Steinle JJ, Meininger CJ, ChowdhuryU,WuG, Granger HJ (2003).Role of ephrin B2 in human retinal endothelial cell proliferation and migration. Cell Signal 15: 1011-1017.
43. le Noble F, Moyon D, Pardanaud L, et al. (2004). Flow regulates arterialvenous differentiation in the chick embryo yolk sac. Development 131: 361-375.
44. Dixit VM, Green S, Sarma V, et al. (1990). Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem 265: 2973-2978.
45. Holzman LB, Marks RM, Dixit VM (1990). A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 10: 5830-5838.
46. Cheng N, Chen J (2001). Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNKdependent but nuclear factor-kappa B-independent mechanism. J Biol Chem 276: 13771-13777.
47. Abdollahi A, Hahnfeldt P, Maercker C, et al. (2004). Endostatin's antiangiogenic signaling network. Mol Cell 13: 649-663.
48. Cheng N, Brantley D, Fang WB, et al. (2003). Inhibition of VEGFdependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5: 445-456.
49. Mukouyama YS, Shin D, Britsch S, Taniguchi M, Anderson DJ (2002). Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109: 693-705.
50. Masood R, Xia G, Smith DL, et al. (2005). Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood 105: 1310-1318.
51. Shin D, Garcia-Cardena G, Hayashi SI, et al. (2001). Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, marks subsets of microvessels at sites of adult neovascularization. Dev Biol 230: 139-150.
52. Visconti RP, Richardson CD, Sato TN (2002). Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). PNAS 99: 8219-8224.
53. Rossant J, Howard L (2002). Signaling pathways in vascular development. Annu Rev Cell Dev Biol 18: 541-573.
54. Zhong TP, Childs S, Leu JP, Fishman MC (2001). Gridlock signalling pathway fashions the first embryonic artery. Nature 414: 216-220.
55. Yuan K, Hong TM, Chen JJ, Tsai WH, Lin MT (2004). Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis. Blood 104: 1025-1033.
56. Brantley-Sieders DM, FangWB, Hicks DJ, et al. (2005). Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 19: 1884-1886.
57. Depaepe V, Suarez-Gonzalez N, Dufour A, et al. (2005). Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 435: 1244-1250.
58. Wang Z, Cohen K, Shao Y, et al. (2004). Ephrin receptor, EphB4, regulates ES cell differentiation of primitive mammalian hemangioblasts, blood, cardiomyocytes, blood vessels. Blood 103: 100-109.
59. Wang Z, Miura N, Bonelli A, et al. (2002). Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells. Blood 99: 2740-2747.
60. McBride JL, Ruiz JC (1998). Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech Dev 77: 201-204.
61. Flenniken AM, Gale NW, Yancopoulos GD, Wilkinson DG (1996). Distinct and overlapping expression patterns of ligands for Eph-related receptor tyrosine kinases during mouse embryogenesis. Dev Biol 179: 382-401.
62. Takahashi H, Ikeda T (1995). Mol cloning and expression of rat and mouse B61 gene: implications on organogenesis. Oncogene 11: 879-883.
63. Stadler HS, Higgins KM, Capecchi MR (2001). Loss of Eph-receptor expression correlates with loss of cell adhesion and chondrogenic capacity in Hoxa13 mutant limbs. Development 128: 4177-4188.
64. Wang HU, Chen ZF, Anderson DJ (1998). Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741-753.
65. Gerety SS, Wang HU, Chen ZF, Anderson DJ (1999). Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4: 403-414.
66. Othman-Hassan K, Patel K, PapoutsiM,et al. (2001). Arterial identity of endothelial cells is controlled by local cues. Dev Biol 237: 398-409.
67. GoettschW, Augustin HG, Morawietz H (2004). Down-regulation of endothelial ephrinB2 expression by laminar shear stress. Endothelium 11: 259-265.
68. Claxton S,FruttigerM (2005). Oxygen modifies artery differentiation and network morphogenesis in the retinal vasculature. Dev Dyn 233: 822-828.
69. Hall SM, Hislop AA, Haworth SG (2002). Origin, differentiation, maturation of human pulmonary veins. Am J Respir Cell Mol Biol 26: 333-340.
70. Risau W (1997). Mechanisms of angiogenesis. Nature 386: 671-674.
71. Oike Y, Ito Y, Hamada K, et al. (2002). Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood 100: 1326-1333.
72. Gerety SS, Anderson DJ (2002). Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 129: 1397-1410.
73. Makinen T, Adams RH, Bailey J, et al. (2005). PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19: 397-410.
74. Cowan CA, Yokoyama N, Saxena A, et al. (2004). Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development. Dev Biol 271: 263-271.
75. Zhang XQ, Takakura N, Oike Y, et al. (2001). Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2(+) endothelial cells. Blood 98: 1028-1037.
76. Helbling PM, Saulnier DM, Brandli AW (2000). The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis. Development 127: 269-278.
77. Hafner C, Schmitz G, Meyer S, et al. (2004). Differential gene expression of Eph receptors and Ephrins in benign human tissues and cancers. Clin Chem 50: 490-499.
78. GaleNW, Baluk P, Pan L, et al. (2001). Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 230: 151-160.
79. Red-Horse K, Kapidzic M, Zhou Y, et al. (2005). EPHB4 regulates chemokineevoked trophoblast responses: a mechanism for incorporating the human placenta into the maternal circulation. Development 132: 4097-4106.
80. Yuan K, Jin YT, Lin MT (2000). Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis. J Periodontal Res 35: 165-171.
81. Vihanto MM, Plock J, Erni D, et al. (2005). Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J 19: 1689-1691.
82. Suenobu S, Takakura N, Inada T, et al. (2002). A role of EphB4 receptor and its ligand, ephrin-B2, in erythropoiesis. Biochem Biophys Res Commun293: 1124-1131.
83. Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
84. Hess AR, Seftor EA, Gardner LM, et al. (2001). Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 3250-3255.
85. Kataoka H, Igarashi H,Kanamori M, et al. (2004). Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 95: 136-141.
86. Papoutsi M, Othman-Hassan K, Christ B, Patel K,Wilting J (2002). Development of an arterial tree in C6 gliomas but not in A375 melanomas. Histochem Cell Biol 118: 241-249.
87. Martiny-Baron G, Korff T, Schaffner F, et al. (2004). Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6: 248-257.
88. Andres AC, Munarini N, Djonov V, et al. (2003). EphB4 receptor tyrosine kinase transgenic mice develop glomerulopathies reminiscent of aglomerular vascular shunts. Mech Dev 120: 511-516.
89. LiuW, Jung YD, Ahmad SA, et al. (2004). Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer. British J Cancer 90: 1620-1626.
90. ZamoraDO, Davies MH, Planck SR, Rosenbaum JT, PowersMR (2005). Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. Invest Ophthalmol Vis Sci 46: 2175-2182.
91. Murai KK, Nguyen LN, Koolpe M, et al. (2003). Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol Cell Neurosci 24: 1000-1011.
92. Koolpe M, Burgess R, Dail M, Pasquale EB (2005). EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 280: 17301-17311.
93. XiaG,Kumar SR, Masood R, et al. (2005). Up-Regulation of EphB4 in Mesothelioma and its biological significance. Clin Cancer Res 11: 4305-4315.
94. Xia G, Kumar SR, Masood R, et al. (2005). EphB4 expression and biological significance in prostate cancer. Cancer Res 65: 4623-4632.
95. DuxburyMS, Ito H, ZinnerMJ, AshleySW,Whang EE (2004). EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23: 1448-1456.
96. Koolpe M, Dail M, PasqualeEB (2002). An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 277: 46974-46979.
97. Carles-Kinch K, Kilpatrick KE, Stewart JC, KinchMS (2002). Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62: 2840-2847.
98. Zisch AH, Zeisberger SM, Ehrbar M, et al. (2004). Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. Biomaterials 25: 3245-3257.